The ELL/MLLT1 dual-color assay described herein entails co-hybridization of probes for the ELL and MLLT1 gene regions, each labeled in a different fluorochrome to allow differentiation between genes involved in 11q;19p chromosome translocations in interphase or metaphase cells. In t(11;19) acute leukemia cases, gain of a signal easily pinpoints the specific translocation breakpoint to either 19p13.1 or 19p13.3 and 11q23. In the re-evaluation of our own cases in light of the FISH data, the 19p breakpoints were re-assigned in two patients, underscoring a certain degree of difficulty in determining the precise 19p breakpoint in acute leukemia specimens in the context of a clinical cytogenetics laboratory. Furthermore, we speculate that the ELL/MLLT1 probe set should detect other 19p translocations that involve these genes with partners other than MLL. Accurate molecular classification of leukemia is becoming more important as targeted therapies are developed and diseases are further sub-classified based on the presence of particular genetic mutations. Distinction of the correct breakpoint, and the gene involved on 19p, is a worthy goal for diagnosis of patients with these cytogenetic aberrations.
The Philadelphia chromosome (Ph), the cytogenetic hallmark of chronic myelogenous leukemia (CML) encodes p210
BCR-ABL fusion protein with enhanced tyrosine kinase activity. In vitro and animal model studies confirm the primary pathogenic role of p210 BCR-ABL fusion protein in the initiation and maintenance of CML, and this has led to the successful development of kinase inhibitors such as imatinib in the control of the disease. In contrast, Ph chromosome-positive acute leukemia poses a biologic and clinical challenge given the difficulty in distinguishing de novo acute leukemia from blast-crisis presentation of CML, the role of p210 BCR-ABL versus p190
BCR-ABL protein kinases, and the variability of outcome and experience with use of imatinib. We describe a patient who presented with Ph þ acute myeloid leukemia (AML) with two additional clonal markers, in which imatinib unmasked the Ph chromosome as a secondary genetic change.
A 49-year-old lady was admitted for pallor, weight loss and poor appetite. There was no splenomegaly. Hemoglobin was 3.6 g/dl, platelet 295 000/ml and white blood cells 137 Â 10 9 /l. Peripheral blood showed 65% blasts, 14% neutrophils and 7% myeloid precursors. There was no basophilia. Marrow aspirate confirmed AML with 74% blasts and chromosome analysis showed 45,XX,inv(3)(q21q26),À7,t(9;22)(q34; q11.2) [12] . Reverse transcriptase-polymerase chain reaction (RT-PCR) for BCR-ABL showed only the e1a2 transcripts. Fluorescence in situ hybridization (FISH) analysis of 300 marrow cells using dual fusion translocation probes (D-FISH, Vysis, Downers Grove, IL, USA) 1 showed 83% were positive for BCR-ABL. The patient failed two cycles of AML induction chemotherapy using daunorubicin and cytarabine with persistent leukemia and 78% of marrow cells positive for BCR-ABL by FISH. Imatinib 600 mg daily was then started, bone marrow examination 6 weeks later still showed 15% blasts. FISH studies showed no BCR-ABL-positive cells (sensitivity 0.3%); however, 39% marrow cells, including segmented neutrophils, were positive for monosomy 7 using the a-satellite sequences in the centromeric region of chromosome 7 (CEP7,D7Z1, Vysis). Cytogenetics showed poor growth, but one metaphase showed 45,XX,inv(3)(q21q26),À7. Taken together, these studies provide evidence that the Ph þ translocation is secondarily acquired in an initial clone characterized by inv(3)(q21q26),À7, which was unmasked after the imatinib treatment. After 5 months of imatinib treatment, marrow blasts increased to 40%. FISH for BCR-ABL remained negative (also negative with the sorted CD34 þ / CD38 þ and CD34 þ /CD38-population) whereas À7 was present in 82% of the marrow cells. Quantitative PCR analysis was not performed. However, with nested RT-PCR using sets of BIOMED primers 2 the e1a2 transcript was still detectable suggesting presence of a very small and quiescent population of imatinib-resistant BCR-ABL-positive leukemic stem cells.
There are only a few reports on the use of imatinib in Ph þ AML. [3] [4] [5] [6] [7] Most cases reporting molecular remission with imatinib had short follow-up and long-term clinical and molecular data is not available. Our case of AML with 45,XX,inv(3)(q21q26),À7, t(9;22)(q34;q11.2) shows two recognized secondary cytogenetic anomalies in advanced CML, that is, monosomy 7 and chromosome aberrations involving band 3q21or 3q26, 8 which initially would have suggested a case of CML blast crisis. However, simultaneous presence of À7 and inv(3)(q21q26) in blastic CML is rare (http://cgap.nci.nih.gov/Chromosomes). We propose that owing to the secondary nature of the Ph chromosome, the rarity in which these three cytogenetic changes are found together in blast crisis, the lack of p210 BCR-ABL protein transcript and the absence of splenomegaly, our case is more in keeping with de novo Ph þ AML over myeloid blastic CML. This is confirmed by FISH studies, which revealed the Ph chromosome is acquired as a late event during clonal evolution. It is salutary to note that combination of FISH and RT-PCR analysis was needed to avoid the erroneous conclusion of imatinib resistance as the size of the BCR-ABL clone went down which is not compatible with BCR-ABL-dependent imatinib resistance. Molecular biology is a powerful tool for investigating acute myeloid leukemia (AML). Given that concerted efforts have documented the reliability and clinical utility of the real-time quantitative polymerase chain reaction (RQ-PCR) for detecting fusion transcripts in AML, 1 it is not surprising that similar assays have been sought for in the sizeable fraction of AML cases without balanced translocations. The Wilms' tumor gene 1 (WT1) has received close attention in this respect. Initially described in childhood genitourinary cancers, the gene has subsequently been shown to be overexpressed in a number of different cancers. Although its exact function in the evolvement of a malignant clone is still a matter of debate, its role as an minimal residual disease (MRD) target in myelodysplastic syndrome and AML is now amply documented. 2, 3 Indeed, recent data from our laboratory suggest that the assay is able to predict relapse months ahead of morphological relapse. 2, 4 In de novo AML relapses are often thought to emerge from exactly the same clone as at diagnosis. This is in contrast to the situation in, for example, pre-B acute lymphoid leukemia, where IgH gene rearrangements have disclosed clonal instability.
In this report, we present evidence that clonal heterogeneity with regard to WT1 may be present at diagnosis and that chemotherapy-resistant subclones can be selected for during chemotherapy.
A 5-year-old boy was diagnosed with AML-M6 in April 2003. The immunophenotype was CD13 þ , CD14À, CD33þ , CD117 þ , and HLA class II þ . Karyotypic analysis did not demonstrate abnormalities (46,XY [25] ). In addition, no recurrent balanced translocations could be found by multiplex PCR 5 and the patient was negative for internal tandem duplication of the FLT3 gene. Two courses of induction chemotherapy were necessary to obtain complete remission (CR). He was treated according to NOPHO-AML93 protocol and completed therapy in September 2003. He remained in CR1 until March 2004, at which time relapse with an identical immunophenotype, morphology and karyotype was diagnosed. He received reinduction
